Group 1 - The company has approved participation in the auction for an 81.96% stake in Kasma Holdings, owned by the Chinese Academy of Sciences, through a board resolution [1] - The auction does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [1] - The company will sign a property transaction contract within five working days and pay the transaction price and service fees to the designated account [1] Group 2 - The transaction aims to broaden the company's product sales channels, enhance product development capabilities, integrate upstream and downstream resources, and improve market competitiveness and profitability [2]

Core Insights - Aladdin (688179) reported a closing price of 15.0 yuan as of August 8, 2025, with a decrease of 0.86% and a turnover rate of 1.59% [1] - The company experienced a net outflow of main funds amounting to 14.45 million yuan, accounting for 18.21% of the transaction amount [1] Financial Performance - For the first quarter of 2025, Aladdin's total operating revenue reached 130 million yuan, reflecting a year-on-year growth of 32.20% [1] - The net profit attributable to shareholders was 24.18 million yuan, showing a year-on-year increase of 41.35% [1] - The company's non-recurring net profit was 23.82 million yuan, with a year-on-year growth of 41.86% [1] - Key financial ratios include a current ratio of 4.839, a quick ratio of 2.548, and a debt-to-asset ratio of 36.36% [1] Company Overview - Shanghai Aladdin Biochemical Technology Co., Ltd. was established in 2009 and is located in Shanghai, primarily engaged in the manufacturing of chemical raw materials and products [2] - The company has a registered capital of 1.413 billion yuan and a paid-in capital of 656.85 million yuan [1] - The legal representative of the company is Xu Jiuzhen [1] Investment and Intellectual Property - Aladdin has made investments in 8 companies and participated in 5,000 bidding projects [2] - The company holds 75 trademark registrations and 104 patents, along with 38 administrative licenses [2]

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-054 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于参与竞拍喀斯玛控股有限公司股权的进展公告 三、本次交易对公司的影响 本次交易旨在拓宽公司产品的销售渠道，提高产品开发能力，整合上下游资 源，提升公司的市场竞争力和盈利能力，有利于公司和投资者利益。 四、风险提示 一、交易基本情况 公司将根据有关部门意见有序推进后续交易，并及时履行信息披露义务，持 续披露后续进展情况。敬请广大投资者理性投资，注意投资风险。 2025 年 7 月 4 日，公司召开第四届董事会第四十次会议及第四届监事会第 二十四次会议，审议通过了《关于参与竞拍中国科学院控股有限公司持有的喀斯 玛控股有限公司 81.96%的股权的议案》，同意公司参与中科院控股所持标的股份 的竞拍。本次交易不构成关联交易，亦不构成《上市公司重大资产重组管理办法》 规定 ...

Core Insights - Shanghai Aladdin Biochemical Technology Co., Ltd. and Fipeng Biotechnology Co., Ltd. have established Dongguan Aladdin Biotechnology Co., Ltd. to create a comprehensive biotechnology platform covering raw materials, reagents, and medical devices, accelerating global strategic expansion in the life sciences sector [1][2] - The establishment of Dongguan Aladdin is a significant strategic move for Aladdin, aiming for technological breakthroughs and market expansion in the life sciences raw materials and reagents field, thereby enhancing profitability and industry position [1] - The collaboration with Fipeng is expected to leverage its advantages in the research, production, and sales of in vitro diagnostic reagent raw materials, further expanding Aladdin's business boundaries in the life sciences sector [1] Business Scope - The new company's business scope includes technical services, manufacturing and sales of specialized chemical products, and production and sales of medical devices, indicating a broad business layout [2] - The company will focus on the research and production of immunological and molecular raw materials, fully automated luminescence devices, and supporting consumables tailored to the needs of research clients [2]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 一、交易概述 上海阿拉丁生化科技股份有限公司（以下简称"阿拉丁"或"公司"）拟以增资、认购老股方式对上海雅酶 生物医药科技有限公司（以下简称"目标公司"或"雅酶生物"）进行投资，认购目标公司一定的新增注册 资本及认购老股（"本次投资"）。本次投资分两步走，第一步由公司先按14,000万元的估值向目标公司 增资2,470万元，取得目标公司增资后15%的股权；第二步由公司按16,470万元的估值受让原股东持有的 目标公司（增资后）10%的股权，股权转让总对价为1,647万元。本次投资下投资方合计出资4,117万 元。本次投资完成后，公司将持有雅酶生物25%的股权。具体内容详见公司于2025年4月23日在上海证 券交易所网站(www.sse.com.cn)披露的《上海阿拉丁生化科技股份有限公司关于自愿披露对外投资上海 雅酶生物医药科技有限公司的公告》（公告编号：2025-025）。 二、交易进展 近日，雅酶生物已完成工商登记手续，工商登记信息如下： 公司名称：上海雅酶生物医药科技 ...

Group 1 - The company, Shanghai Aladdin Biochemical Technology Co., Ltd., plans to invest in Shanghai Yamei Biomedical Technology Co., Ltd. through capital increase and share acquisition, with a total investment of 41.17 million RMB [2] - The investment will be executed in two steps: first, a capital increase of 24.7 million RMB for a 15% stake at a valuation of 140 million RMB; second, acquiring a 10% stake from existing shareholders for 16.47 million RMB [2] - Upon completion of the investment, the company will hold a total of 25% equity in Yamei Biomedical [2] Group 2 - Yamei Biomedical has completed its business registration, with a registered capital of 1.433154 million RMB and established on March 18, 2019 [3] - The company operates in various fields including technology services, health consulting, cell technology research, and biomedical engineering [3] - The legal representative of Yamei Biomedical is Wu Jun, and it is classified as a limited liability company [3]

证券代码：688179 证券简称：阿拉丁 公告编号：2025-053 （公告编号：2025-025）。 二、交易进展 近日，雅酶生物已完成工商登记手续，工商登记信息如下： 公司名称：上海雅酶生物医药科技有限公司 转债代码：118006 转债简称：阿拉转债 上海阿拉丁生化科技股份有限公司 关于对外投资上海雅酶生物医药科技有限公司的进 展暨完成工商登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、交易概述 上海阿拉丁生化科技股份有限公司（以下简称"阿拉丁"或"公司"）拟以 增资、认购老股方式对上海雅酶生物医药科技有限公司（以下简称"目标公司" 或"雅酶生物"）进行投资，认购目标公司一定的新增注册资本及认购老股（"本 次投资"）。本次投资分两步走，第一步由公司先按 14,000 万元的估值向目标公 司增资 2,470 万元，取得目标公司增资后 15%的股权；第二步由公司按 16,470 万元的估值受让原股东持有的目标公司（增资后）10%的股权，股权转让总对价 为 1,647 万元。本次投资下投资方合计出资 4,1 ...

一、交易概述 | 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-053 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于对外投资上海雅酶生物医药科技有限公司的进 展暨完成工商登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 主要股东： | 股东名称/姓名 | 出资比例 | | --- | --- | | 吴军 | 41.1074% | | 上海阿拉丁生化科技股份有限公司 | 25.0000% | | 上海熠廷企业管理合伙企业（有限合伙） | 10.4700% | | 上海佑登企业管理合伙企业（有限合伙） | 9.2325% | | 上海卉烨企业管理合伙企业（有限合伙） | 8.9550% | | 上海洛哈企业管理合伙企业（有限合伙） | 5.2351% | | 合计 | 100.0000% | 特此公告。 上海阿拉丁生化科技股份有限公司 董事会 上海阿拉丁生化科技股份有限公司（以下简称"阿拉丁"或 ...

| 证券代码：688179 | 证券简称：阿拉丁 | 公告编号：2025-052 | | --- | --- | --- | | 转债代码：118006 | 转债简称：阿拉转债 | | 上海阿拉丁生化科技股份有限公司 关于设立合资公司的进展暨完成工商登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、交易概述 法定代表人：李传宝 上海阿拉丁生化科技股份有限公司（以下简称"阿拉丁"或"公司"）广东 菲鹏生物有限公司（以下简称"菲鹏生物"）于 2025 年 1 月 3 日签署《原料试剂 孵化项目交易框架协议》，通过原料、试剂及解决方案定制化开发及资产、技术 许可及服务转让等一系列交易，双方有意将共同新发起设立的项目公司孵化成为 具备原料和试剂及解决方案供应、原料和试剂生产及自主研发能力的公司。具体 内容详见公司于 2025 年 1 月 7 日在上海证券交易所网站(www.sse.com.cn)披露 的《上海阿拉丁生化科技股份有限公司关于自愿披露签订战略合作框架协议暨设 立合资公司的公告》（公告编号：2025-00 ...

Core Viewpoint - Aladdin (688179.SH) plans to bid for an 81.96% stake in Kasma Holdings from the Chinese Academy of Sciences Holdings Co., Ltd. with a starting price of 202 million yuan, aiming to enhance market competitiveness through resource integration and sales channel expansion [1][3]. Group 1: Company Overview - Kasma Holdings, established in 2016, focuses on technology services, investment consulting, and research resource promotion, with projected revenues exceeding 160 million yuan in both 2023 and 2024, and net profits of 54.02 million yuan and 25.67 million yuan respectively [3]. - Aladdin is a domestic supplier of research reagents, covering high-end chemicals and life sciences through its "Aladdin" brand, with a projected sales revenue of 534 million yuan in 2024, representing a year-on-year growth of 32.44% [3]. Group 2: Auction Details - The auction for Kasma Holdings will consist of a free bidding period from July 7, 10:00 to 10:10, followed by a timed bidding period, with the final outcome remaining uncertain [3]. - If the bidding is successful, Aladdin will further strengthen its research service ecosystem; if unsuccessful, the company emphasizes that its existing business will not be significantly affected [3].